Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | HTR1E | P28566 | 1/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | GRN | P28799 | 2/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3632991 | 1.00 | NPSR1 (0.62) | NPSR1MAPTMAPK1ALDH1A1GAA | |
| SCHEMBL3804271 | 0.83 | NPC1 (0.58) | NPSR1MAPTMAPK1ALDH1A1GAA | |
| SCHEMBL4913028 | 0.83 | NPC1 (0.58) | NPSR1MAPTMAPK1ALDH1A1GAA | |
| SCHEMBL4490129 | 0.73 | GRN (0.78) | NPSR1MAPTMAPK1ALDH1A1GAA | |
| SCHEMBL3628257 | 0.70 | ESRRG (0.67) | NPSR1MAPTLMNAKMT2AMEN1 | |
| SCHEMBL3628253 | 0.70 | ESRRG (0.67) | NPSR1MAPTLMNAKMT2AMEN1 | |
| SCHEMBL1898164 | 0.66 | NPSR1 (0.89) | NPSR1MAPTMAPK1ALDH1A1GAA | |
| SCHEMBL1669206 | 0.66 | MAPT (0.78) | NPSR1MAPTGAALMNAKDM4E | |
| SCHEMBL3630396 | 0.66 | MAPT (0.78) | NPSR1MAPTGAALMNAKDM4E | |
| SCHEMBL1672357 | 0.66 | MEN1 (0.78) | MAPTLMNAKDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | INSTITUTE FOR ONEWORLD HEALTH | 2008-10-30 | — | — | US | claimed |
| US-8283351-B2 | Inhibiting cyctic fibrosis transmembrane conductance regulator polypeptide ; therapy for diarrhea and polycystic kidney disease | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283351-B2 | Inhibiting cyctic fibrosis transmembrane conductance regulator polypeptide ; therapy for diarrhea and polycystic kidney disease | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283351-B2 | Inhibiting cyctic fibrosis transmembrane conductance regulator polypeptide ; therapy for diarrhea and polycystic kidney disease | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-10-09 | — | — | US | disclosed |
| US-20120219543-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISORDERS OF GLUCOSE HOMEOSTASIS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2012-08-30 | — | — | US | disclosed |
| EP-2142498-A2 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | Institute for Oneworld Health (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | INSTITUTE FOR ONEWORLD HEALTH | 2008-10-30 | — | — | US | disclosed |
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | INSTITUTE FOR ONEWORLD HEALTH | 2008-10-30 | — | — | US | disclosed |
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | INSTITUTE FOR ONEWORLD HEALTH | 2008-10-30 | — | — | US | disclosed |
| WO-2008121877-A2 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | INSTITUTE FOR ONEWORLD HEALTH (US) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120219543-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISORDERS OF GLUCOSE HOMEOSTASIS | CFTR, IAPP, GPR119 | NPSR1 2638/4885MAPT 4663/4885MAPK1 3174/4885 |
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | CFTR, PKD1, PKD2 | NPSR1 2994/4885MAPT 4853/4885MAPK1 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.